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Summary
Background:  Hemodialysis  (HD)  is  an  important  risk  factor  for  progression  of  aortic  valve  stenosis
(AS). However,  there  are  varying  degrees  of  disease  progression  among  patients  with  AS  on  HD.
The aim  of  this  study  was  to  ﬁnd  determinants  of  rapid  progression  of  AS  in  patients  on  HD.
Methods: We  enrolled  30  patients  with  AS  on  HD  with  a  mean  follow-up  period  of  4  years.
The peak  pressure  gradient  (PPG)  between  the  initial  echocardiography  and  the  last  echocar-
diography  at  least  3  months  interval  (PPG)  was  adopted  as  the  indicator  of  AS  progression.
We divided  the  patients  into  two  groups  according  to  PPG  per  year  [rapid  progression
(PPG >  4.5  mmHg/year),  slow  progression  (PPG  <  4.5  mmHg/year)]  and  compared  the  clinical
characteristics  between  the  two  groups.
Results:  Overall  mean  PPG  was  4.5  mmHg/year.  Systolic  blood  pressure  (SBP),  serum  calcium,
and calcium-phosphate  product  were  signiﬁcantly  higher  in  rapid  progression  group  compared
with slow  progression  group  (p  <  0.05).
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ntroductionemodialysis  (HD)  is  an  important  risk  factor  for  progres-
ion  of  aortic  valve  stenosis  (AS).  Previous  reports  showed
ccelerated  progression  of  AS  in  HD  patients  compared  with
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Rapid progression group (n=15) Slow progression group (n=15)
peak PG (PPG) > 10 mmHg
Hemodialysis Patients in 2005-2009  
Follow-up echo 
mean follow-up period 4.0 year
n=131 
Baseline echo
n=41    
Mesurement of Progression of Aortic Stenosis
raey/gHmm5.4<GPPraey/gHmm5.4>GPP
n= 30   
mean PPG / year 4.5 mmHg
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non-HD  patients  [1,2]. It  has  been  reported  that  the  pro-
gression  of  AS  is  associated  with  the  same  risk  factors  as
cardiovascular  disease  including  serum  low-density  lipopro-
tein  level  [3—5]. However  there  are  few  reports  that  have
investigated  whether  the  rapid  progression  of  AS  is  asso-
ciated  with  a  high  event-free  rate  in  HD  patients  during
follow-up  period.  Therefore  the  aim  of  this  study  was  to
investigate  the  determinants  of  progression  of  AS  and  iden-
tify  the  high-risk  group  of  rapid  AS  progression,  mortality,  or
cardiac  events  in  patients  with  AS  on  HD.
Methods
Patient  inclusion
Follow-up  echocardiography  recorded  at  least  3  months
later  was  included.  Patients  without  initial  echocardiogra-
phy  data  or  biochemistry  data  were  excluded.  This  study
was  performed  with  the  Helsinki  Declaration  and  approved
by  the  institutional  review  board.  All  of  the  patients  had  pre-
viously  granted  permission  for  use  of  their  medical  records
for  research  purposes.
Baseline  data
Physical  examination,  medication,  and  biochemistry  data
were  examined  at  the  time  of  baseline  echocardiography.
Serum  concentration  of  calcium  was  corrected  by  the  con-
centration  of  albumin.
Echocardiography
Echocardiography  was  obtained  by  using  commercially  avail-
able  ultrasound  systems  (SSA-380A,  Toshiba,  Tokyo,  Japan
or  SONOS-7500,  Phillips,  Bothell,  WA,  USA).  Diastolic  dimen-
sion,  systolic  dimension,  intraventricular  septum,  posterior
wall,  and  left  atrium  dimension  were  measured.  Ejection
fraction  (EF)  was  calculated  by  Teichholz  method.  Peak  aor-
tic  jet  ﬂow  was  measured  on  the  continuous-wave  Doppler
echocardiograms.
Long-term  data
Follow-up  was  performed  via  ofﬁce  visit,  letter,  or  telephone
contact.  Patients  were  followed  until  ﬁrst  events  [death  or
aortic  valve  replacement  (AVR)]  or  until  the  study  end  date
(December  31st,  2009).  Patients  who  did  not  experience  an
outcome  of  interest  were  censored  at  the  last  known  date
of  contact.  The  study  endpoints  were  all-cause  death  and
AVR.  The  indication  of  operation  was  symptomatic  (syncope,
chest  pain,  and  congestive  heart  failure)  and  severe  [peak
pressure  gradient  (PPG)  over  50  mmHg  or  aortic  valve  area
(AVA)  under  1.0  cm2]  AS  with  preserved  EF  (EF  >  50%)  or  mod-
erate  (PPG  over  36  mmHg  or  AVA  under  1.5  cm2)  AS  with
reduced  EF  (EF  <  40%).Statistical  analysis
Data  are  presented  as  frequencies  and  percentages  for
categorical  variables  and  means  ±  standard  deviation  for
o
b
Iigure  1  Patients’  inclusion  ﬂow  chart.  PG,  pressure  gradi-
nt.
ontinuous  variables.  Patient  characteristics  were  com-
ared  between  the  groups  divided  by  the  PPG.  Data
ere  analyzed  with  Mann—Whitney  U-test.  Categorical  data
ere  compared  using  Fisher’s  exact  test.  Multivariate  logis-
ic  analysis  was  applied  to  investigate  whether  the  two
roups  of  PPG  predict  adverse  events  event  (death  or
VR)  after  adjusting  other  variables.  In  this  model,  we
sed  mildly  signiﬁcantly  different  characteristics  (p  <  0.10)
etween  the  two  groups  as  the  independent  variables.  All
ariables  were  simultaneously  adjusted  in  one  step.  Haz-
rd  ratios  and  the  95%  conﬁdence  intervals  were  calculated.
he  Kaplan—Meier  curves  stratiﬁed  according  to  the  PPG
ere  drawn.  A  p-value  <  0.05  was  considered  to  indicate
tatistical  signiﬁcance.  All  analyses  were  performed  using
tatistical  software,  SPSS  13.0/Windows  (SPSS  Inc.,  Chicago,
L,  USA).
esults
mong  131  HD  patients  who  were  admitted  to  Jichi  Med-
cal  University  Saitama  Medical  Center  between  July  2005
nd  December  2009,  echocardiography  was  performed  in
ll  patients  (Fig.  1).  Among  131  patients,  41  patients  had
S  with  PPG  over  10  mmHg.  Of  the  41  patients,  echocar-
iography  was  performed  at  least  twice  in  30  of  them.
hese  30  patients  were  divided  into  two  groups  according  to
ean  PPG:  rapid  progression  group  (n  =  15,  mean  PPG  per
ear  >  4.5  mmHg),  and  slow  progression  group  (n  =  15,  mean
PPG  per  year  <  4.5  mmHg)  (Fig.  1).
Clinical  characteristics  of  the  patients  are  shown  in
ables  1  and  2.  Although  there  was  a  trend  toward  higher
ge  in  the  rapid  progression  group  (p  =  0.096),  there  was  no
igniﬁcant  difference  between  the  two  groups.  Mean  base-
ine  PPG  of  the  two  groups  was  not  signiﬁcantly  different
Fig.  2).  Mean  PPG  per  year  was  11.1  ±  6.43  mmHg  in  the
apid  progression  group  per  year  versus  −2.18  ±  8.25  mmHg
er  year  in  the  slow  progression  group  (p  <  0.001).  Sys-
olic  blood  pressure,  serum  calcium  level,  and  product  of
alcium—phosphate  were  signiﬁcantly  higher  in  the  rapid
rogression  group.  Corrected  calcium  level  and  product
f  calcium  and  phosphate  were  also  signiﬁcantly  different
etween  the  two  groups.
Multivariate  Cox  regression  analysis  is  shown  in  Table  3.
n  this  model,  the  factors  with  p  <  0.10  in  univariate  analysis,
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Table  1  Clinical  characteristics  of  aortic  stenosis  in  patients  on  hemodialysis.
Rapid  progression  (n  =  15)  Slow  progression  (n  =  15)  p-Value
Age  (years)  73.6  ±  6.1  69.8  ±  7.5  0.096
Male sex,  no.  (%)  6  (40%)  8  (53%)  0.72
Height (m)  1.58  ±  0.08  1.57  ±  0.08  0.84
Weight (kg)  57.8  ±  7.56  53.9  ±  11.2  0.36
Diabetes mellitus,  no.  (%)  7  (67%)  10  (47%)  0.46
Hypertension,  no.  (%) 15  (100%)  15  (100%)  1.00
Dyslipidemia,  no.  (%) 3  (20%) 7  (47%)  0.25
Current smoker,  no.  (%) 8  (53%) 6  (40%) 0.72
Atrial ﬁbrillation,  no.  (%) 2  (13%) 2  (13%) 1.00
Lipid
Total cholesterol  (mg/dl)  111  ±  78  138  ±  64  0.98
Triglyceride  (mg/dl)  116  ±  81  138  ±  64  0.18
HDL-cholesterol  (mg/dl)  41  ±  8  43  ±  13  0.50
Medication,  no.  (%)
Angiotensin-converting  enzyme  inhibitor  5  (33%)  5  (33%)  1.00
Angiotensin  receptor  blocker  12  (%)  10  (%)  0.68
Calcium antagonists  11  (73%)  10  (67%)  1.00
-Blockers 3  (20%)  5  (33%)  0.34
-Blockers 2  (13%)  4  (27%)  0.65
Diuretics 5  (33%)  4  (27%)  1.00
Statin 1  (7%)  2  (13%)  1.00
Phosphate adsorbent  9  (60%)  6  (40%)  0.47
Vitamin D3 6  (40%)  5  (33%)  1.00
Etiology of  hemodialysis,  no.  (%)
Diabetic  nephropathy 7  (47%)  8  (53%)
Chronic glomerulonephritis  4  (27%)  2  (13%)
Hypertensive  nephropathy 1  (7%)  3  (20%)
Chronic nephritis 1  (7%) 1  (7%)  0.74
IgA nephropathy 1  (7%) 1  (7%)
Chronic nephropathy 1  (7%) 1  (7%)
Rapid progressive  glomerulonephritis 1  (7%) 0  (0%)
Etiology of  AS,  no.  (%)
Degenerative 14  (46.7%) 15  (100%)
Rheumatic 0  (0%) 0  (0%) 1.00
Bicuspid 1  (3.33%)  0  (0%)
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ge,  systolic  blood  pressure,  and  serum  calcium  were
dopted  as  independent  variables.  Systolic  blood  pressure
nd  serum  calcium  were  strong  predictors  of  adverse  events
ven  after  adjusting  for  these  factors  (Table  3).
The  relationship  between  the  progression  of  AS  and  death
r  AVR  is  shown  in  Fig.  2.  There  were  15  events  (4  deaths
nd  6  AVR  in  rapid  progression  group,  2  deaths  and  3  AVR  in
low  progression  group)  during  a  mean  period  of  4.0  years
p  =  0.07,  Table  2,  and  Fig.  2).
iscussion
ur  study  showed  that  the  overall  change  in  mean  PPG  per
ear  in  AS  patients  on  HD  was  4.5  mmHg.  Systolic  blood
ressure  and  serum  calcium  concentration  were  strongly
ssociated  with  rapid  progression  in  HD  patients.  Moreover
ur  study  also  showed  that  the  clinical  event  rate  was  higher
n  the  rapid  progression  group  than  in  the  slow  progression
roup.
A
a
b
[Previous  reports  showed  that  the  mean  PPG  per  year
f  AS  in  HD  patients  was  3.9  mmHg  [6]  and  the  mean  PPG
er  year  in  non-HD  patients  was  1.0  mmHg  [7].  Our  results,
.5  mmHg,  are  similar  to  AS  in  HD  in  the  previous  study  [6].
hese  results  also  conﬁrmed  that  the  progression  of  AS  in
D  is  more  rapid  compared  with  non-HD  patients.
Earlier  studies  identiﬁed  male  gender,  history  of
therosclerosis,  and  impaired  renal  function  as  the  deter-
inants  of  AS  progression  in  non-HD  patients  [2,8,9].
ypercholesterolemia  is  reported  to  be  a  risk  factor  for  the
evelopment  and  progression  of  calciﬁc  AS  [3,10],  although
ecent  studies  throw  doubt  on  this  hypothesis  [4].  It  is
eported  that  aortic  valve  calciﬁcation  is  also  accelerated
n  HD  patients  [11]. Increased  calcium—phosphate  product,
econdary  hyperparathyroidism,  and  excess  vitamin  D  are
hought  to  be  responsible  for  calcium  deposition  [12—15].
ccelerated  calcium  deposition  not  only  in  the  coronary
rteries  but  also  on  the  aortic  valves  may  comprise  a  mor-
id  problem  in  HD  patients  [12,15—17].  Owens  and  Otto
18]  reported  that  the  conventional  atherosclerotic  factors
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Table  2  Univariate  analysis  of  determinants  of  the  progression  of  aortic  stenosis.
Rapid  progression  (n  =  15)  Slow  progression  (n  =  15)  p-Value
Follow-up  (year)  4.02  ±  2.11  4.05  ±  2.84  0.82
Hemodialysis  (year)  9.53  ±  4.27  9.80  ±  4.96  0.72
Peak pressure  gradient  (mmHg/year)  11.1  ±  6.43  −2.18  ±  8.25  <0.001
Ejection fraction  (%)  59.7  ±  10.8  65.1  ±  9.7  0.19
Systolic blood  pressure  (mmHg)  161  ±  21.5  142  ±  24.4  0.04
Diastolic blood  pressure  (mmHg) 80.2  ±  13.7  71.4  ±  14.2  0.12
Heart rate  (/min) 74.9  ±  12.0 74.8  ±  16.1  0.76
LDL-cholesterol  (mg/dl) 97.4  ±  40.2 93.2  ±  34.5 0.65
Hemoglobin  A1C  (%) 5.3  ±  0.8 5.6  ±  0.8 0.38
C-reactive  protein  (mg/dl) 0.32  ±  0.21 0.28  ±  0.45 0.11
Serum Ca  (mg/dl)  9.66  ±  1.05  8.87  ±  0.91  0.02
Serum albumin  (mg/dl)  3.80  ±  0.53  3.80  ±  0.55  0.88
Corrected serum  Ca  (mg/dl)  10.0  ±  0.89  8.87  ±  1.34  0.01
Serum P  (mg/dl)  5.66  ±  1.00  5.47  ±  1.17  0.90
Ca ×  P  54.5  ±  9.94  48.2  ±  10.1  0.10
Corrected Ca  ×  P  56.5  ±  10.5  48.3  ±  11.6  0.11
Death 4  (26%)  2  (13%)  0.33
Aortic valve  replacement  6  (40%)  3  (20%)  0.21
Heart failure  re-hospitalization  2  (13%)  1  (7%)  0.50
Death and  aortic  valve  replacement  10  (67%)  5  (33%)  0.07
LDL, low-density lipoprotein.
Figure  2  The  relationship  between  the  progression  of  aortic  stenosis  and  death  or  aortic  valve  replacement.  AVR,  aortic  valve
replacement;  PPG,  peak  pressure  gradient.
Table  3  Results  of  multivariate  logistic  regression  analysis.
Variables  Odds  ratio  95%CI  p-Value
Age  (+1  year)  1.27  1.00—1.61  0.05
Systolic blood  pressure  (+10  mmHg)  1.06  1.00—1.11  0.04
Serum Ca  (+1  mg/dl)  6.08  1.28—28.8  0.02
CI, conﬁdence interval.
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romote  the  ‘sclerosis  of  the  aortic  valve’  [19], and  the
tenosis  of  aortic  valve  progresses  in  the  later  phase  [18].
ur  results  showed  that  low-density  lipoprotein  cholesterol,
-reactive  protein  [20], and  age  were  not  signiﬁcant  deter-
inants  for  the  progression  of  AS,  while  systolic  blood
ressure,  serum  calcium  level,  and  products  of  calcium  and
hosphate  were  strong  determinants  of  rapid  progression  in
D  patients.  The  patients  on  HD  are  considered  to  be  already
n  the  later  phase  of  the  cascade  of  AS.  These  results  sug-
est  that  calcium  plays  an  important  role  in  the  progression
f  AS  in  patients  on  HD.
The  present  study  also  showed  the  event-free  rate  of
he  rapid  progression  group  was  lower  than  in  the  slow
rogression  group.  The  event-free  rate  in  the  rapid  pro-
ression  group  of  AS  in  HD  is  40%  while  the  event-free
ate  of  the  slow  progression  group  is  67%  during  4  years
f  follow-up  (Table  2).  A  previous  report  from  Japan  has
hown  that  the  mean  4-year  survival  rate  of  HD  patients  is
0%  [21]. Our  results  show  that  the  freedom  from  death  or
VR  in  AS  patients  on  HD  is  worse  than  non-AS  patients  on
D.
tudy limitations
 retrospective  study  design  with  a  relatively  small  sample
ize  in  a  single  center  may  pose  a  risk  for  patient  selection
ias.  The  interval  between  baseline  and  follow-up  echocar-
iography  was  different  among  patients.  The  data  of  serum
oncentration  and  blood  pressure  were  collected  at  the  start
f  follow-up,  which  may  not  reﬂect  the  data  of  the  whole
linical  course.
Severe  calciﬁcation  of  aortic  valve  often  makes  acoustic
hadow  in  echocardiography  and  interrupts  accurate  mea-
urement  and  AVA  is  not  always  measured  exactly  in  all  cases
f  AS  with  severe  calciﬁcation  in  HD  patients.  In  this  study,
0  cases  were  interrupted  to  measure  accurate  AVA  with
evere  calciﬁcation.  For  these  reasons,  PPG  was  adopted  as
 parameter  of  progression  of  AS  in  HD,  instead  of  AVA,  how-
ver  the  weak  point  of  PPG  was  its  dependence  on  cardiac
unction  and  some  cases  with  deteriorating  EF  in  the  rapid
rogression  group  may  be  included  in  the  slow  progression
roup.
In  this  study,  parathyroid  hormone  was  checked  only  in  10
ases,  because  the  measurement  of  serum  parathyroid  hor-
one  was  limited  only  to  the  patients  whose  serum  calcium
nd  phosphate  level  was  treated  by  standard  therapy  and
ecreased  to  the  adequate  cut-off  level  by  the  Japanese
uidelines  about  the  treatment  of  the  patients  with  sec-
ndary  hyperparathyroidism  in  HD  patients  in  2006.  The
yperparathyroidism  was  treated  by  vitamin  D3  and  phos-
hate  absorbent  according  to  the  guidelines.
onclusions
ur  study  showed  that  high  systolic  blood  pressure  and
erum  calcium  level  were  associated  with  rapid  progres-
ion  of  AS  in  patients  on  chronic  HD.  It  is  an  open  question
hether  the  careful  clinical  follow-up  of  AS  and  the  control
f  blood  pressure  and  serum  calcium  may  lower  the  event
ate  of  AS  patients  on  HD.M.  Hoshina  et  al.
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